New real-world data findings along with new product evolutions demonstrate why the UroLift® System is the right solution for most BPH patients
The UroLift ATC System builds on the highly successful UroLift System and features an enhanced delivery device tip designed to make it easier for urologists to treat BPH patients with a median lobe. The new UroLift 2 System is an evolution of the UroLift System platform and is engineered with innovative design features to enhance user confidence and ease of use including an ergonomic single trigger, an improved suture cutter, and simplified workflow.1 The eco-friendly Delivery Handle and implant cartridge design requires 66% less storage space, and generates nearly 50% less waste material per procedure, as compared to the prior generation UroLift System.1 Both new products support the continued utilization of the UroLift System in its full indication, which includes prostate volume <=100 cc, lateral and median lobe hyperplasia, in men 45 years of age or older.
Presentations of new data on the UroLift System include (all times are Pacific Daylight Time [PDT]):
- PD23-02: “Comparing Predictors of Durability After Prostatic Urethral Lift (PUL) Between Real-World and Controlled Studies” will be presented by
Claus Georg Roehrborn , M.D.,2 at9:40am .
- LBA01-01: “UroLift PUL compared to Rezūm, TURP and Greenlight PVP:
U.S. Medicare and commercial claims analysis reveals lowest complications for PUL and highest retreatment for Rezūm” will be presented bySteven A. Kaplan , M.D.,3 at1:00pm .
Society for Benign Prostate Disease at the AUA- “Product and Clinical Evolution of the UroLift System” will be presented by
Brian Mazzarella , M.D.,4 at10:15am .
- “Product and Clinical Evolution of the UroLift System” will be presented by
About the UroLift® System
The UroLift® System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 45 years or older (50 years outside
About Teleflex Interventional Urology
The Teleflex Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive, and clinically effective devices that address unmet needs in the field of urology. Our focus is on improving the standard of care for patients with BPH using the UroLift® System, a minimally invasive, permanent implant system that treats symptoms while preserving sexual function.*5-7 Learn more at NeoTract.com.
About
Contacts:
For
Vice President, Investor Relations and
Vice President, Investor Relations
investors.teleflex.com
610-948-2836
Media:
nicole@healthandcommerce.com
*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.
† Management estimate based on product sales and average units per procedure.
References
1. Data on file.
2.
3.
4.
5. Roehrborn, J Urology 2013 L.I.F.T. Study
6. AUA BPH Guidelines 2003, 2020
7. McVary, J Sex Med 2016
Source:
2021 GlobeNewswire, Inc., source